Ashwin Sapra

Ashwin routinely advises clients in the pharmaceutical, healthcare and life sciences sector on regulatory compliance and IP issues arising out of regular business operations and complex transactions.

• Advising on regulatory issues pertaining to development, approval, manufacture, and marketing of drugs, cosmetics and medical devices in India. Ashwin routinely advises clients on regulatory, ethical, product liability and compliance issues pertaining to clinical trials in India and further advises clients on government and industry anti-kickback statutes and issues related to drug promotion in terms of physician-patient and drug representative- physician interactions. He regularly engages in review and analysis of regulatory approvals and registration licenses of target companies as part of business incorporation and due diligence efforts in large scale business merger/ acquisition matters. Ashwin also advises bio-tech companies on regulatory requirements that govern access and use of domestic biological resources.
• Advising clients in the pharmaceutical and bio-technology/ life sciences sector on IP portfolio protection strategy, management, prosecution, enforcement and litigation. Apart from deep rooted experience in supervising freedom-to-operate searches for domestic and foreign clients. He has extensive experience in conducting IP portfolio audits for clients and providing guidance on the setting up of in-house standard operating procedures pertaining to IP asset protection and has previously been involved in creating IP concept presentations to educate client employees on IP issues.

• Ranked ‘Band 2’ at Chambers and Partners, 2022-2024
• “A- List Lawyer” at IBLJ 2024
• “Leading Individual” for Life Sciences and Healthcare, Legal 500 2024
• “Recommended Lawyer” for Life Sciences and Healthcare, Legal 500 2023
• Ranked ‘Highly Regarded’ at IFLR1000, 2023

• Bar Council of Delhi and Delhi High Court Bar Association